يعرض 101 - 120 نتائج من 14,939 نتيجة بحث عن '(( significant increase decrease ) OR ( significantly ((worse decrease) OR (we decrease)) ))', وقت الاستعلام: 0.43s تنقيح النتائج
  1. 101
  2. 102
  3. 103
  4. 104

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  5. 105

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  6. 106

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  7. 107
  8. 108

    BMI groups by SES. حسب Krystal Hunter (6820052)

    منشور في 2025
    الموضوعات:
  9. 109

    BMISES_Data_Part2. حسب Krystal Hunter (6820052)

    منشور في 2025
    الموضوعات:
  10. 110
  11. 111
  12. 112
  13. 113

    BMISES_Data_Part1. حسب Krystal Hunter (6820052)

    منشور في 2025
    الموضوعات:
  14. 114
  15. 115
  16. 116

    Diagram of study population. حسب Krystal Hunter (6820052)

    منشور في 2025
    الموضوعات:
  17. 117
  18. 118
  19. 119
  20. 120